Navigation Links
United Therapeutics Corporation Announces Stock Split To Be Effected as a Stock Dividend
Date:9/1/2009

SILVER SPRING, Md., Sept. 1 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that its Board of Directors has approved and declared a stock split. The stock split will be effected in the form of a stock dividend, in which one share of United Therapeutics common stock will be distributed for each share of common stock issued and outstanding (or held in treasury) at the close of business on the record date, September 14, 2009. The additional shares of common stock are scheduled to be distributed on September 22, 2009, to all shareholders of record by BNY Mellon, United Therapeutics' transfer agent. United Therapeutics expects that its common stock will begin to trade on the NASDAQ Global Select Market on a split-adjusted basis beginning on September 23, 2009.

"Just as the recent approval of our new medicine, Tyvaso, has provided doctors and patients with a 2-for-1 therapeutic opportunity, by having both inhaled and parenteral forms of treprostinil to prescribe, today's announcement provides shareholders with a 2-for-1 investment opportunity, by doubling the number of outstanding shares from approximately 27 million to 54 million," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "Even with this split, our number of outstanding shares is still well below that of other similar stage biotechnology companies."

About United Therapeutics

United Therapeutics is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer.

Forward-looking Statements

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, the future timing and benefits of the stock split and the opportunities created by the launch of Tyvaso. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and current reports on Form 8K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of September 1, 2009, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason. [uthr-g]

Tyvaso is a trademark of United Therapeutics Corporation.


'/>"/>
SOURCE United Therapeutics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States
2. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
3. Wyeth Provides Regulatory Update on Prevnar 13* in the United States
4. Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
5. United States FDA Clears the REGEN Trial to Test Biohearts Combination Gene and Stem Cell Therapy in Heart Failure Patients
6. United Therapeutics Corporation to Announce Second Quarter 2009 Financial Results Before Market Open on Friday, July 31, 2009
7. LS9's UltraClean Diesel Exceeds United States & Brazilian Fuels Specifications
8. NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State
9. Americans United for Life: Obamas Disbanding Bioethics Council Raises Troubling Questions
10. MedMira Strengthens North American Sales Channels, Adding VWR as Distributor for the United States
11. The Chiesi Group Lands in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... 17, 2017 The Global Implantable Biomaterials ... of around 7.5% over the next decade to ... the prominent trends that the market is witnessing ... & graft transplant surgeries and medical implants and ... is categorized into immunomodulatory biomaterials, natural, polymers, hydrogels ...
(Date:1/17/2017)... Ind. , Jan. 17, 2017  Zimmer Biomet ... fourth quarter and full-year 2016 sales and earnings conference ... Tuesday, January 31, 2017, at 8 a.m. Eastern Time.  ... will be made available at 7:30 a.m. Eastern Time ... live audio webcast can be accessed via Zimmer Biomet,s ...
(Date:1/17/2017)... , Jan. 17, 2017 Research ... report "Molecular Diagnostics - Technologies, Markets and Companies" ... ... diagnostics has increased remarkably during the past few years. More ... developing molecular diagnostics and 342 of these are profiled in ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... 2016 annual meeting of the North American Spine Society (NASS)1 demonstrate high ... the majority of cases, when PEEK-OPTIMA™ HA Enhanced is used for interbody-fusion ...
Breaking Biology Technology:
(Date:12/15/2016)... , Dec 15, 2016 ... Research and Markets has announced the addition ... offering. The report forecasts the global military biometrics market ... The report has been prepared based on an in-depth market ... and its growth prospects over the coming years. The report also includes ...
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in ... biometrics market" The mobile biometrics market is expected to ... 49.33 billion by 2022, at a CAGR of 29.3% ... factors such as the growing demand for smart devices, ... transactions. "Software component is expected to grow ...
(Date:12/8/2016)... 2016  Singulex, Inc., the leader in Next Generation ... a license and supply agreement with Thermo Fisher Scientific, ... Singulex access to Thermo Scientific BRAHMS PCT (Procalcitonin), a ... used to diagnose systemic bacterial infection and sepsis and ... aid in assessing the risk of critically ill patients ...
Breaking Biology News(10 mins):